Shui‐Mei Khoo

International Medical University — Malaysia

Medicine · Health Sciences

11h-index1.5kcitations13works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Drug Transport and Resistance Mechanisms(4), Drug Solubulity and Delivery Systems(3), Epilepsy research and treatment(2), Pharmacogenetics and Drug Metabolism(2), Lipid Membrane Structure and Behavior(2)

Publications13 total

Cytotoxic effects of opiate agonist loperamide hydrochloride on human oral cancer cells—an invitro study
Exploration of Medicine·2025Open Access
An investigation of the factors which impact on the absorption and metabolism of halofantrine
Figshare·2017Open Access
A rapid and sensitive HPLC–MS method for the detection of plasma and cellular rifampicin
Journal of Chromatography B·2007· 40 cited
A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats
International Journal of Pharmaceutics·2007· 169 cited
Hexosomes formed from glycerate surfactants—Formulation as a colloidal carrier for irinotecan
International Journal of Pharmaceutics·2006· 137 cited
Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems
International Journal of Pharmaceutics·2006· 325 cited
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals
Clinical Pharmacology & Therapeutics·2005· 73 cited
Intestinal Lymphatic Transport of Halofantrine Occurs After Oral Administration of a Unit-Dose Lipid-Based Formulation to Fasted Dogs
Pharmaceutical Research·2003· 144 cited
A physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs
Journal of Pharmaceutical Sciences·2002· 37 cited
A Conscious Dog Model for Assessing the Absorption, Enterocyte‐Based Metabolism, and Intestinal Lymphatic Transport of Halofantrine
Journal of Pharmaceutical Sciences·2001· 110 cited
The formulation of Halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: Physical stability and absolute bioavailability assessment
International Journal of Pharmaceutics·2000· 85 cited
Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole
Journal of Pharmaceutical Sciences·1998· 25 cited
Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine
International Journal of Pharmaceutics·1998· 393 cited

Frequent Co-authors

Christopher J. H. Porter(7), William N. Charman(6), Glenn A. Edwards(5), Ben J. Boyd(3), Darryl V. Whittaker(3), Greg Davey(2), D.J. Back(2), Andrew Humberstone(1), Gail Davey(1), David M. Shackleford(1), Lisa M. Almond(1), Damitha Edirisinghe(1), Mary E. D’Alton(1), Alec Bonington(1), Ruben C. Hartkoorn(1), J. Tjia(1), Catriona Waitt(1), Masautso Chaponda(1), Geraint Davies(1), Alison Ardrey(1)